Vanqua Bio
Chicago, US · Founded 2019 · Delaware corporation · 11 known investors
Find your way into Vanqua Bio
464 people in our graph share verified history with the Vanqua Bio team — schools, employers, funds. One of them is your warm intro.
Liz Westhouseunlockedknows Jim Sullivan, Ph.D. · together at Northwestern University (overlapped)
×3knows the team · via AbbVie
×2knows the team · via Northwestern University
×6knows the team · via Trinity College Dublin
Founders & leadership
RS
Rand SutherlandExecutive
JS

James SullivaninExecutiveJames Sullivan is an R&D executive with extensive experience in pharmaceutical and biotech development, having led over 100 compounds into clinical trials across multiple disease areas including cancer, hepatitis C, Alzheimer's disease, and inflammatory conditions. He has experience with company formation and serves as Executive Officer and Director of Vanqua Bio.
Board
JS

BD
Bernard DavitianBoard director
UC
Uya ChuluunbaatarBoard director
MA

Investors · 11
Pontifax Venture CapitalHerzeliya · $6.3M – $128M
Avoro VenturesreportedNew York
Casdin CapitalreportedNew York
OrbiMedreported · 3 sourcesNew York · $1M – $75Mvia Mona Ashiya · board
Osage University PartnersreportedBala Cynwyd
Also in the syndicate · 6
Eli LillyEli Lilly and CompanyLogos CapitalOmega FundsleadPontifaxSurveyor Capital
Reported raises · per SEC filings
Form D private placements$136M disclosed across 3 rounds · 2019–2024
▶$45MraisedJul 2024 · 12 investors · BiotechnologyRule 506(b)
▶$45MraisedJul 2024 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan SilversteinDirector
- Rand SutherlandDirector
- Bernard DavitianDirector
- Uya ChuluunbaatarDirector
- James SullivanExecutive Officer, Director
- Mona AshiyaDirector
- Offering amount
- $45M
- Amount sold
- $45M
- First sale
- Feb 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$85MraisedSep 2021 · 11 investors · BiotechnologyRule 506(b)
▶$85MraisedSep 2021 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mona AshiyaDirector
- Viola MeehanExecutive Officer
- Bernard DavitianDirector
- Sara NayeemDirector
- James SullivanExecutive Officer, Director
- Jonathan SilversteinDirector
- Stephen SquintoDirector
- Offering amount
- $85M
- Amount sold
- $85M
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$6MraisedOct 2019 · 1 investors · Other TechnologyRule 506(b)
▶$6MraisedOct 2019 · 1 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- JONATHAN SILVERSTEINExecutive Officer, Director
- JAMES SULLIVANExecutive Officer, Director
- MONA ASHIYADirector
- Offering amount
- $18M
- Amount sold
- $6M
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- Who are Vanqua Bio's investors?
- Vanqua Bio's investors include Pontifax Venture Capital, Avoro Ventures, Casdin Capital, OrbiMed, Osage University Partners.
- How much funding has Vanqua Bio raised?
- Vanqua Bio has disclosed $136M raised across 3 rounds.
- Where is Vanqua Bio headquartered?
- Vanqua Bio is headquartered in Chicago, US.



